The Uromigos Episode 64: Second Uromigos Debate—Nobel Laureate Bill Kaelin on New Biomarker Versus New Drugs in RCC

Dr. Bill Kaelin (Nobel Laureate) and Tom Powles (keen cyclist) extend their discussion from KCRS20 in the second Uromigos Debate, “New Drugs vs New Biomarkers.”

Related Episodes

The Uromigos Episode 162: Debate—Adjuvant Nivolumab for Bladder Cancer
The Uromigos Episode 63: The First Uromigos Debate—Front-Line Immune Therapy Versus Maintenance Avelumab in Bladder Cancer
The Uromigos Episode 56: Matt Galsky on ESMO 2020 Immune Therapy Data in Bladder Cancer
The Uromigos Episode 67: The Third Debate—PD1/VEGF Versus PD1/CTLA4 for Front-Line Renal Cancer